Restless Legs Syndrome

Resmed Acquires Noctrix Health to Enter Restless Legs Syndrome Market

The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.

Restless Legs Syndrome

New AASM Guidelines Overhaul Restless Legs Syndrome Treatment

The updated guideline emphasizes iron evaluation and supplementation while recommending against the use of dopamine agonists due to risks of symptom worsening.

Restless Legs Syndrome

FDA Grants De Novo Status for Wearable System to Treat RLS

The prescription therapy is intended to treat symptoms of moderate to severe restless legs syndrome and improve sleep quality in patients refractory to medications.

Restless Legs Syndrome Biomarker Could Be Hiding in Periodic Limb Movements of Sleep

May 25, 2023 | Restless Legs Syndrome

A meta-analysis identifies a potential polysomnographic signal of RLS more sensitive and specific than the PLMS index.

How to Reduce Augmentation Risk in Restless Legs Syndrome

May 9, 2023 | Prescription Drugs, Restless Legs Syndrome

Physicians who regularly manage RLS patients offer real-world advice on ways to prevent augmentation. For patients already experiencing augmentation, new therapy options may be on the way.

MCRA Helps Noctrix Secure Marketing Authorization for RLS Therapy Device

May 8, 2023 | FDA, Restless Legs Syndrome, Restless Legs Syndrome Devices

The device is indicated to reduce symptoms of primary moderate-severe restless legs syndrome and improve sleep quality in adults refractory to medications.

Accuracy of Restless Legs Syndrome Screening Questionnaires Questioned

Mar 22, 2023 | Questionnaires, Restless Legs Syndrome

For epidemiological studies, screening instruments used to diagnose restless legs syndrome in the absence of clinical interviews aren’t cutting it, experts say.

CDC Changes Opioid Prescribing Guidelines

Nov 18, 2022 | Restless Legs Syndrome

The 2022 CDC Opioid Prescribing Guidelines released on November 3, 2022, replaced earlier guidelines that had led to confusion, misinterpretation, and faulty application by medical providers, according to a statement from the RLS Foundation.

Research Needs Rodent Models of Restless Legs Syndrome, But Assessing RLS in Mice Is Tricky

Nov 14, 2022 | Restless Legs Syndrome

The International Restless Legs Syndrome Study Group publishes a new guideline on construct validity of rodent models of RLS.

Restless Legs Syndrome Patients See 61% Decrease in Sleep Problems When Taking Pycnogenol Extract

Sep 15, 2022 | Over-the-Counter Treatments, Restless Legs Syndrome

A new study found Pycnogenol French maritime pine bark extract to significantly relieve and prevent symptoms associated with restless legs syndrome.

RLS Foundation Study: Restless Legs Syndrome Takes High Toll on Health

Jun 8, 2022 | Restless Legs Syndrome

In ODYSSEY II, 2,745 people with confirmed RLS completed a survey about RLS diagnosis and severity, associated medical conditions, treatments, and medical care.

Don’t Light the Fuse of Restless Legs Syndrome with Dopamine Agonists

May 4, 2022 | Prescription Drugs, Restless Legs Syndrome

Twenty percent of restless legs syndrome patients are already on higher-than-recommended doses of dopamine agonists, says John Winkelman, MD, PhD.

Sleep Apnea Drug Candidate Developer Incannex to Acquire RLS Therapy Candidate Developer APIRx

May 3, 2022 | Emerging Compounds, Obstructive Sleep Apnea, Restless Legs Syndrome

The acquisition of APIRx will significantly strengthen Incannex’s position with regard to cannabinoid and psychedelic treatment development.

COVID Pandemic Linked to Worsening Restless Legs Syndrome

Mar 14, 2022 | Podcasts, Restless Legs Syndrome

Ben Wipper discusses the study “Restless legs syndrome severity in the National RLS Opioid Registry during the COVID-19 pandemic.”

Yes, Kids Can Get Restless Legs Syndrome, Too

Feb 3, 2022 | Restless Legs Syndrome

A patient writes into the Mayo Clinic News Network to ask if their child might be experiencing restless legs syndrome.

‘Dopamine Agonists Should Not Be a First-line Treatment for Restless Legs Syndrome’

Jan 14, 2022 | Restless Legs Syndrome

The Restless Legs Syndrome Foundation updates its algorithm for the management of RLS. The most notable change is a firm pivot away from dopamine agonist medications as first-line treatments.